The goal of this study is to develop a biorepository to store pediatric biospecimen from nephrology cohorts for on-going and future research studies. These studies plan to advance the state of science in the hopes to develop novel diagnostic approaches and identify therapeutic targets to prevent and/or treat pediatric disease involving the kidneys.

This study is for patients with bladder cancer. The study is being done to see if by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy can lower the chance of the patient's bladder cancer from growing or spreading.

This study is for patients with bladder cancer. The study is being done to see if by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy can lower the chance of the patient's bladder cancer from growing or spreading.

Composur will be a prospective study in patients with overactive bladder (OAB) in the United States (US) who are treated with the drug vibegron as single drug therapy for the treatment of OAB. The aim of this study is to understand how the study drug performs in real-world every day practice. This is a observational study that will require you will be asked to attend 4 visits at the study clinic and 2 telephone calls: Day 1 (Visit 1), then at 4-6 weeks (Visit 3), 12-20 weeks (Visit 4) and 24-36 weeks (Visit 5) after Day 1. Visit 2 will be a telephone call and at 12 months (Visit 6), one additional telephone call will occur. A monthly contact after the initial visit will occur for one year but can be extended to 2 years upon the Sponsor's decision.

This study is for patients with urothelial cancer. The study is being done to see if by adding a drug called cabozantinib to standard maintenance treatment abelumab will prolog life for patients with metastatic urothelial cancer.

This study is for patients that have already received standard treatments for their cancer and their cancer has gotten worse or returned after their last treatment. The purpose of this study is to learn about the effects of the study drug XL092 when given alone, in combination with atezolizumab, and in combination with avelumab by testing its safety, the ability of your body to accept the drug(s), to measure the drug(s) and/or its break-down products levels in your blood, and how your body reacts to the drug(s). This research study will be the first time XL092 alone or in combination with atezolizumab will be given to people. The study drugs in this research have not been approved by the United States Food and Drug Administration (FDA). There are two parts in this study, a Dose Escalation part and a Cohort Expansion part. The first part of the study was the Dose Escalation phase, when different participants were given different doses of the study drug until the safest, most effective dose was found; this part of the study has been completed. The study is now enrolling to the Cohort Expansion part of this study, where the dose that has been determined to be safe will be given to more participants with different types of cancer. The Dose Escalation part of this study has stopped and the safe dose has been found. This study is now enrolling to the Cohort Expansion part of this study, where the safe dose of the study drug found in the Dose Escalation part will be given to more participants with different types of cancer. Participants will either be assigned to the treatment group that will receive XL092 alone or the treatment group that XL092 in combination with atezolizumab. Which treatment group they are assigned depends on the type of cancer they have. TXL092 is in tablet form taken by mouth. Avelumab will be given as an intravenous (IV) infusion once every 2 weeks at the study site. Atezolizumab will be given as an intravenous (IV) infusion once every 3 weeks at the study site. Total study duration is expected to be about 6 months but participants could be in the study for up to 2 years.

This study will collect prospective data on clinical indications, outcomes, and adverse events related to Prostatic Artery Embolization (PAE) at the Medical University of South Carolina. Patients undergoing surgical treatment for benign prostatic obstruction causing LUTS will also be allowed to enroll in this registry for the purposes of comparison. Patients will be followed at 1, 3, and 12 months post-procedure, for a period of up to 5 years. Patients will remain enrolled in the registry for a period of 5 years.